These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 11289137

  • 1. Bisphosphonate treatment inhibits the growth of prostate cancer cells.
    Lee MV, Fong EM, Singer FR, Guenette RS.
    Cancer Res; 2001 Mar 15; 61(6):2602-8. PubMed ID: 11289137
    [Abstract] [Full Text] [Related]

  • 2. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW.
    J Urol; 2003 Jul 15; 170(1):246-52. PubMed ID: 12796698
    [Abstract] [Full Text] [Related]

  • 3. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
    Dumon JC, Journé F, Kheddoumi N, Lagneaux L, Body JJ.
    Eur Urol; 2004 Apr 15; 45(4):521-8; discussion 528-9. PubMed ID: 15041119
    [Abstract] [Full Text] [Related]

  • 4. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
    Derenne S, Amiot M, Barillé S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R.
    J Bone Miner Res; 1999 Dec 15; 14(12):2048-56. PubMed ID: 10620064
    [Abstract] [Full Text] [Related]

  • 5. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
    Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC.
    Cancer Res; 2000 Nov 01; 60(21):6001-7. PubMed ID: 11085520
    [Abstract] [Full Text] [Related]

  • 6. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
    Tanaka T, Kawashima H, Ohnishi K, Matsumura K, Yoshimura R, Matsuyama M, Kuratsukuri K, Nakatani T.
    Anticancer Res; 2009 Apr 01; 29(4):1089-94. PubMed ID: 19414350
    [Abstract] [Full Text] [Related]

  • 7. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
    Yang M, Burton DW, Geller J, Hillegonds DJ, Hastings RH, Deftos LJ, Hoffman RM.
    Clin Cancer Res; 2006 Apr 15; 12(8):2602-6. PubMed ID: 16638872
    [Abstract] [Full Text] [Related]

  • 8. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
    Montague R, Hart CA, George NJ, Ramani VA, Brown MD, Clarke NW.
    Eur Urol; 2004 Sep 15; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
    [Abstract] [Full Text] [Related]

  • 9. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ, Mancini I.
    Support Care Cancer; 2002 Jul 15; 10(5):399-407. PubMed ID: 12136223
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS.
    Eur J Pharmacol; 2007 Sep 10; 570(1-3):27-37. PubMed ID: 17640631
    [Abstract] [Full Text] [Related]

  • 11. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
    Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM.
    Calcif Tissue Int; 2004 Jul 10; 75(1):71-7. PubMed ID: 15037971
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
    Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, Séronie-Vivien S.
    BMC Cancer; 2006 Mar 15; 6():60. PubMed ID: 16539721
    [Abstract] [Full Text] [Related]

  • 13. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 14. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts.
    Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, Brodie AM, Bielawska A, Smyth MJ.
    Prostate; 2004 Mar 01; 58(4):382-93. PubMed ID: 14968439
    [Abstract] [Full Text] [Related]

  • 15. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
    Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M.
    Cancer Res; 2005 Oct 01; 65(19):8818-25. PubMed ID: 16204052
    [Abstract] [Full Text] [Related]

  • 16. Effect of mammalian lignans on the growth of prostate cancer cell lines.
    Lin X, Switzer BR, Demark-Wahnefried W.
    Anticancer Res; 2001 Oct 01; 21(6A):3995-9. PubMed ID: 11911282
    [Abstract] [Full Text] [Related]

  • 17. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells.
    Iguchi K, Tatsuda Y, Usui S, Hirano K.
    Eur J Pharmacol; 2010 Sep 01; 641(1):35-40. PubMed ID: 20519142
    [Abstract] [Full Text] [Related]

  • 18. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer.
    Qadan LR, Perez-Stable CM, Anderson C, D'Ippolito G, Herron A, Howard GA, Roos BA.
    Biochem Biophys Res Commun; 2001 Aug 03; 285(5):1259-66. PubMed ID: 11478793
    [Abstract] [Full Text] [Related]

  • 19. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
    Green JR.
    Acta Oncol; 2005 Aug 03; 44(3):282-92. PubMed ID: 16076701
    [Abstract] [Full Text] [Related]

  • 20. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
    Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL.
    Clin Cancer Res; 2003 Jan 03; 9(1):295-306. PubMed ID: 12538482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.